Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celadrin is a proprietary blend of cetylated, esterified fatty acids (CFAs) used as a dietary supplement and topical analgesic for the relief of joint and muscle pain associated with osteoarthritis, strains, and sprains. Developed and marketed by Factors Group of Nutritional Products, it is available in oral softgel and topical cream formulations. The mixture typically includes cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl laureate, cetyl palmitate, and cetyl oleate. Its mechanism of action involves the stabilization of cell membranes, reduction of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor (TNF), and inhibition of the cyclooxygenase-2 (COX-2) enzyme. By enhancing membrane fluidity and integrity, Celadrin aims to reduce inflammation and support joint health and mobility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celadrin.